PGx-guided therapies in non-cancer areas (e.g., cardiovascular disease, mental illness) have primarily focused on the cytochrome P450 (CYP) family of pharmacogenes, which are involved in the metabolism of nearly 20% of commonly used drugs [39]. The gene discussed is PPIG; the disease is psychiatric disorder.